Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and improving patient outcomes, said Joe DePinto, MBA, of McKesson.
Joe DePinto, MBA
Advertisement
Articles by Joe DePinto, MBA
Joe DePinto, MBA, of McKesson; Kathi Henson, MBA, of Orsini; and Natalie Bedford of McKesson discuss how Asembia's AXS25 Specialty Summit fosters collaboration among industry leaders, exploring technology trends to enhance specialty pharmacy and patient care delivery.
Advertisement
Latest Updated Articles
Cell and Gene Therapies Hold Promise, but Access Barriers PersistPublished: December 19th 2024 | Updated:
Specialty Pharmacy Trends and Technology at Asembia AXS25Published: May 4th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
